<DOC>
	<DOCNO>NCT01732549</DOCNO>
	<brief_summary>The purpose study confirm tasquinimod use maintenance therapy active tolerable patient metastatic castrate-resistant prostate cancer progress first chemotherapy docetaxel .</brief_summary>
	<brief_title>A Proof Concept Study Maintenance Therapy With Tasquinimod Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After First Line Docetaxel Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically document prostate cancer evidence metastatic disease radiological evaluation , without symptom ( define accord BPI scale , use analgesic narcotic ) Has receive first line docetaxel base chemotherapy ( monotherapy ) every 3 week schedule administration corticosteroid minimum 6 cycle cumulative dose ≥360 mg/m2 . Any combination investigational non investigational agent prohibit Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Docetaxelrelated adverse effect must resolve NCICTCAE v4.03 ( Common Toxicity Criteria Adverse Effects ) Grade ≤1 . Chemotherapyinduced alopecia Grade 2 peripheral neuropathy allow No progressive disease end docetaxel treatment define accord RECIST criterion , new lesion ( ) assess bone scan elevate prostate specific antigen ( PSA ) three last test PSA3≤PSA2≤PSA1 . The time PSA test preferably least 14 day , however , minimum 7 day acceptable . Note : PSA value round near whole number PSA &gt; 10 ng/mL . If PSA3 value PSA2 , fourth PSA test performed . The PSA4 value equal PSA2 Last dose docetaxel administer 21 42 day randomisation Chemical surgical castration verify level serum testosterone ≤50 ng/dL ( 1.75 nmol/L ) Has concurrent use anticancer agent treatment , follow exception : ongoing treatment luteinising hormonereleasing hormone agonist antagonist , denosumab bisphosphonate ( e.g. , zoledronic acid ) permit started ≥4 week prior Screening . Ongoing treatment keep stable dose regimen Has ongoing treatment warfarin Had prior radiation therapy since start docetaxel . Exceptions may make palliative nonmyelosuppressive radiation therapy administer 2 week prior randomisation Had prior strontium , samarium radium therapy prior treatment tasquinimod , agent antiangiogenic property Has ongoing treatment corticosteroid &gt; 10 mg/day prednisolone equivalent Has prostate cancer pain warrant initiation radiotherapy chemotherapy Has know brain epidural metastasis . Patients previous medullary cord compression without neurological deficit could include Has history malignancy , except adequately treat nonmelanoma skin cancer solid tumour curatively treat , without evidence disease &gt; 5 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>